Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies

被引:2
|
作者
Chernak, Brian J. [1 ,2 ]
Rampal, Raajit K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Leukemia, 1275 York Ave, New York, NY 10021 USA
[2] NewYork Presbyterian Weill Cornell Med Ctr, Dept Med, New York, NY 10021 USA
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; EXTRA-MEDULLARY HEMATOPOIESIS; AGNOGENIC MYELOID METAPLASIA; INTERNATIONAL-WORKING-GROUP; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; RESPONSE CRITERIA; THERAPY; RUXOLITINIB; EFFICACY;
D O I
10.1016/bs.ircmb.2021.07.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extramedullary hematopoiesis (EMH) is often a physiologic response to ineffective marrow production of hematologic cells. While this can be found incidentally in various physiologic and pathophysiologic states, the myeloproliferative neoplasms (MPNs) are some of the most common underlying conditions found in patients with EMH. Although this process can assist with hematologic production in defective states, the burden of EMH can lead to symptomatic discomfort and mechanical obstructive complications, most commonly in the spleen and liver. Here we describe the pathophysiology of EMH, treatment options, including medical, surgical and radiation-based approaches.
引用
收藏
页码:97 / 116
页数:20
相关论文
共 50 条
  • [1] Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
    Tefferi, Ayalew
    Vainchenker, William
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 573 - 582
  • [2] Treatment strategies for myeloproliferative neoplasms
    Heidel, Florian
    ONKOLOGIE, 2022, 28 (08): : 721 - 730
  • [3] General Characteristics and Outcome of Renal Extramedullary Hematopoiesis in Patients with Myeloproliferative Neoplasms: A Literature Review
    Mohamed, Shehab
    Alkhateeb, Mohamed
    Abdalhadi, Ahmed
    Nashwan, Abdulqadir
    Obeidat, Khaldoun
    Imam, Yahya
    Yassin, Mohamed
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S359 - S359
  • [4] Innovative treatment strategies in myeloproliferative neoplasms
    Doehner, K.
    Stegelmann, F.
    Schlenk, R. F.
    ONKOLOGIE, 2011, 34 : 36 - 36
  • [5] Innovative treatment strategies in Myeloproliferative Neoplasms
    Doehner, K.
    Stegelmann, F.
    Griesshammer, M.
    Schlenk, R. F.
    ONKOLOGIE, 2012, 35 : 84 - 84
  • [6] Distinct Histological Patterns of Splenic Extramedullary Hematopoiesis in Myeloproliferative Neoplasms Correlate with Clinical Behavior.
    Prakash, S.
    Hoffman, R.
    Barouk, S.
    Knowles, D. M.
    Orazi, A.
    MODERN PATHOLOGY, 2011, 24 : 316A - 316A
  • [7] Distinct Histological Patterns of Splenic Extramedullary Hematopoiesis in Myeloproliferative Neoplasms Correlate with Clinical Behavior.
    Prakash, S.
    Hoffman, R.
    Barouk, S.
    Knowles, D. M.
    Orazi, A.
    LABORATORY INVESTIGATION, 2011, 91 : 316A - 316A
  • [8] Pathophysiology of thrombosis in myeloproliferative neoplasms
    Landolfi, Raffaele
    Di Gennaro, Leonardo
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (02): : 183 - 186
  • [9] Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
    Kjaer, Lasse
    CANCERS, 2020, 12 (08) : 1 - 21
  • [10] Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
    Lim, Ken-Hong
    Matsuura, Shinobu
    Xu, Bing
    FRONTIERS IN ONCOLOGY, 2021, 11